Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular
Status:
Completed
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate whether the use of Sugammadex for reversing the
neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed
recovery of neuromuscular function. Half of participates will receive Neostigmine with
glycopyrrolate, while the other half will receive Sugammadex.